Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Therapy-related myelodysplastic syndromes-specific risk stratification: Are we putting the cart before the horse?

    ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 09/11/2017 - 9:05am.

  2. Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML

    ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 07/18/2017 - 12:51pm.

  3. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.

    ... 24, 2017 While therapy-related (t)- myelodysplastic syndromes (MDS) have worse outcomes than de novo MDS (d-MDS), some t-MDS patients ...

    Research Article last updated 03/09/2017 - 1:27pm.

  4. Therapy-related myelodysplastic syndromes, or are they?

    ... The incidence of therapy-related myelodysplastic syndromes (t-MDS) is increasing as the number of cancer survivors is increasing. While t-MDS ...

    Research Article last updated 01/26/2017 - 10:08am.

  5. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs. de novo myelodysplastic syndromes: A report on behalf of the MDS clinical research consortium

    ... 23, 2017 While therapy-related (t)-MDS has worse outcomes than de novo MDS (d-MDS), some t-MDS patients ...

    Research Article last updated 02/03/2017 - 10:09am.

  6. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia

    ... January 24, 2013 Therapy-related myelodysplastic syndromes and acute myelogenous leukemia (t-MDS/AML) comprise a poor-risk subset of MDS/AML. Large scale mutation ...

    Research Article last updated 02/04/2013 - 2:39pm.

  7. Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia.

    ... PURPOSE OF REVIEW: Therapy-related myelodysplastic syndromes and acute myelogenous leukemia (t-MDS/AML) comprise an increasingly common, poor-risk disease cohort without ...

    Research Article last updated 02/04/2013 - 2:51pm.

  8. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases

    ... BACKGROUND: TP53 mutation is more prevalent in therapy-related myeloid neoplasms (t-MN) than their de novo ... patients with therapy-related myelodysplastic syndrome (t-MDS)/acute myeloid leukemia (t-AML). Clinical, hematological, and cytogenetic ...

    Research Article last updated 06/03/2015 - 1:04pm.

  9. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.

    ... in patients with primary myelodysplastic syndromes (MDS). However, the clinical importance of BM fibrosis is not clear in therapy-related MDS . We retrieved all therapy-related MDS (t-MDS) cases ...

    Research Article last updated 06/20/2013 - 11:02am.

  10. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases

    ... sequencing-based approach to profile gene mutations in therapy-related myelodysplastic syndromes (t-MDS) and acute myeloid leukemia (t-AML); and compared these findings with ...

    Research Article last updated 03/02/2015 - 2:00pm.